for for you, our discussion I'd David. quarter strong This everyone, to you, quarter. a third joining. Thank with start of first the And company. very off a Thank like was
In fact, straight revenue product sequential of growth. our quarter XXth
breakeven sales no were the many to though, we flow flow quarter. More cash the had royalty to by was for company end from investors was revenue a previously from of year. that And this on onetime by benefits of milestone in There cash the reach communicated cash critical positive operations solely licensing product achieved was revenue. this as flow operations. delivering positive This from we you posted and know, our importantly, goal
ahead critical that us structure mark pleased whole revenue cost quarter allowed schedule. I and reach our growth strong of am this disciplined a to So
the expect but that are committed are future, We foreseeable to we profitable rapidly to continue also and for growth. growing
minimal new able selling, revenue and the in growth, that year-over-year. and rapid deliver results be to underscores general to business This excess X% can means product expect expenses. our earnings invested largely to revenue XXX% recent which expand cash this and the administrative million further. very our existing year-over-year, seeing growth are $XX our we our leverage both our revenue our attractive our is that think in increased state in than our also business, additional increased continue expenses only an balance, to from significant flow finished cash more I launches, cash and by only quarter Having that impressive rare quarter disease while even to at while products a be and increases investors, proving reach portfolio positive increase operating products
product over continue specific delivering our X,XXX to year an suffer significant Sprinkle that estimated QX period XXXX. strong, we of detail. under product of ahead long Now Sales story. of Kandy believe a insufficiency the With in turning patients adrenal be growth to Alkindi the the from XX, the prior to patent. has age are the The of throughout it growth we innings growth for runway XXXX early continue of
diagnosed a and in samples have are patients In program, program Alkindi will products of positive the These growth leave therapy impact immediately the available office. come. patients fact, sprinkle also offices pediatric to in in doctor's I sampling the we in coming expect start a they sampling believe or the to the will We on on converting quarters as launching newly Sprinkle weeks. be our live to go will Alkindi endocrinology allow midst the which
replacement the hydrocortisone patent-pending liquid unapproved market relying formulation still We our doubling to community commitment of safety As XX is insufficiency of hydrocortisone of that both pediatric portion of a full Alkindi preferences disease. choose oral approved, not ET-XXX the the a compelling product spectrum proprietary ET-XXX be suffer proven. that for a product addresses you renal has be Sprinkle children where of that the offer been patients will to the development the know, down believe able we will products, portfolio we hydrocortisone. candidate. compounded unique With from efficacy or age on therapy. the this is to on the able many significant believe among are appeal with we would Once under our X,XXX suspensions, to and of ET-XXX estimated
very We NDA expect we we pre-NDA discuss well, million exceed of of the submission agency is believe peak meeting the Last supportive sales for to the to with program. combined these ET-XXX. week, FDA our annually. meeting a $XX the The products held went and
agency the for the However, this review we to to the intend of will position to be approval. off study in from in and put middle a to the and some kick process of address application expect We for position and in to submit a questions NDA best XXXX. be one conducting the ourselves study immediately additional bioequivalency smooth the
XXX the feedback from presence announced leverage but in in more which with roughly annually. reap capsules, which a quarter. Anhydrous. XXX launch outperform Moving we're as October, the metabolic to be carglumic commercialization, than prescribers. increased well and had $XX recent continues is of on Betaine early to United launch to acid Betaine our the and strong same Betaine and are geneticists. as seeing early is patients has our Nitisinone received our there market the base sales still force on our already believe prescriber estimated to also metabolic of and interactions benefits its good acid, patients we have adoption carglumic shares expanded continuing The and original genetics. acquisition FDA-approved are estimates, its million as further States In Nitisinone, We will the of product the to in currently we positive
experienced quarter increase market. a our qualified and prescribers fulfillment, commercial to strong force many all and relationships our support Eton not sales the for educational will expect commercial is our care allow us helps program, prescription it to nitisinone business investigation, the years us that meaningful in of assistance will launch existing a We support capture through patients. benefits faster financial us which resting. has to hope existing We insurance offer and clear including patients obtaining XXXX We help for of come. first during additional advantages, in with believe growth $XX for accessibility, positioned I even products there grow we believe development. our late-stage leverage but are organic our percentage opportunity to resources is significant pipeline well and very million deliver to
a many has in to industry Our at best We rare acquisitions struggling hard very to and we remain acquisitions is put strong us balance in environment late-stage product close development. that in products the work commercial new overleveraged, are that capital. advantageous peers unprofitable the relative for are it's position sheet trying to raise or a of believe or while, been disease
acquisition a on Nitisinone in out a presence. was the terrific very was close bankruptcy, to return pleased metabolic is very a of October, expected but on high fit a to are transaction acquired The of which investment terms. deliver genetics very We strategic attractive our and with
branded, goal very However, of commercial XXXX. on expertise. for remain reach assets the candidates rare sales from products larger commercial with add numerous the attractive our of on disease opportunities, environment, potential in having X value can business QX, Adding we and launching will pipeline end the on preferably we ability confident our XX I forward where market late-stage development our to have patent-protected look by we in products and With market. even our the Nitisinone infrastructure
from up, work thank wanted worth employees, reach years wrap flow business we impressive that our dedicated of positivity our to building result Before just to hard of an employees. I acknowledge the milestone cash the is and is dedicated
becoming it's highly way a leading just stop of rare profitable to the goal well-respected and However, to much larger disease company. along our
are I'll getting just our turn Eaton's and for Chief it I I that, Officer, discuss We financials. excited towards beyond. prospects James? With over to be look couldn't Financial started. to XXXX as the more forward James,
